Fisher & Paykel Healthcare is a long-term play

Fisher & Paykel Healthcare is a long-term play
Chief executive Lewis Gradon (Image: Fisher & Paykel Healthcare)
Rebecca Howard
Fisher & Paykel Healthcare will benefit from the fact that its nasal high-flow therapy machine became the frontline choice for covid-19, but it won’t happen overnight. “The only real thing that covid-19 changed is that customers have a lot of the hardware,” said chief executive Lewis Gradon. Revenue in the year to March 31, 2019, was just over $1 billion. By the 2021 financial year, it had jumped to nearly $2b as the company moved swiftly to supply hospitals around the world with nasal high-flow therapy mach...

More Markets

NZX-listed Cooks Coffee unfazed by record raw coffee prices
Retail

NZX-listed Cooks Coffee unfazed by record raw coffee prices

This year's 76% hike doesn't affect the firm's outlook, chair says.

NZ sharemarket claws back to end the week up 0.5%
Markets Market close

NZ sharemarket claws back to end the week up 0.5%

Index rumours drive prices on two shares. 

Graham Skellern 13 Dec 2024
Staff leave Meridian after retail 'reset'
Markets

Staff leave Meridian after retail 'reset'

Expect a very different approach from Meridian in 2025, executive says.

John Anthony 13 Dec 2024
NZX, NZSA want level playing field in climate reporting
Markets

NZX, NZSA want level playing field in climate reporting

Climate reporting liabilities for company directors could soon be eased.

Greg Hurrell 13 Dec 2024